- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
New Study in American Institute of Physics' Publication Confirms That Silicon Nanoparticles Used in Octillion's NanoPower Window, When Placed on a Silicon Solar Cell, Can Boost Power, Reduce Energy-Wasting Heat, and Prolong Life of Conventional Solar Cells
Octillion Corp. (OTCBB:OCTL) today announces that a published research study has demonstrated, among other achievements, that the same silicon nanoparticles used in development of the Company's first-of-its-kind transparent glass window capable of generating electricity, are able to drastically increase the power performance of conventional silicon solar cells.
In experiments where silicon nanoparticles were applied on top of solar cells, researchers observed large voltage enhancements with dramatic increases in power ranging from as much as 60-70% in the ultraviolet-blue (UV) range, and further reported a significant boost in power by as much as 10% in the visible light range - a major accomplishment.
"The exceptional power performance of these silicon nanoparticles is a substantial achievement, and is especially significant since our use of these same nanoparticles is key to the development of Octillion's transparent glass windows capable of generating electricity, an innovation that I believe can potentially reduce the harmful environmental impact associated with traditional electrical power generation," explained Mr. Harmel S. Rayat, President and CEO of Octillion Corp.
Mr. Rayat continues, "Of particular note, the nanoparticle layers used in these experiments not only increased power performance of the conventional solar cell, but importantly, these nanoparticles were able to successfully convert the same UV components that typically cause damage and create wasteful heat into useful electrical energy. This process not only increases power, but it also serves to reduce UV damage to the solar cell, thus helping increase its lifespan.
"Above all, the nanoparticles in these studies were in the same size ranges used for our window technology, and were layered to create a transparent film, similar to the desired transparency we aim to achieve with Octillion's NanoPower Windows."
In key experiments, researchers integrated ultrathin films of silicon nanoparticles of 1nm and 3nm in diameter directly onto conventional polycrystalline solar cells (BP Solarex Si cells), forming a transparent layer of silicon nanoparticles; the same transparent nanoparticles used in Octillion's window technology.
Researchers published their breakthrough findings in the August 6, 2007 edition of the American Institute of Physics' highly respected and refereed Applied Physics Letters, ranked in recent years as the world's most highly cited journal in applied physics, and renowned as the premier source for publication of discoveries in physics phenomena for more than 40 years.
About Octillion Corp.
Octillion Corp. is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging solar energy and solar related technologies.
Among our current research and development activities is the development of a patent-pending technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure.
The technological potential of adapting existing glass windows into ones capable of generating electricity from the sun’s solar energy has been made possible through a ground breaking discovery of an electrochemical and ultrasound process that produces identically sized (1 to 4 nanometers in diameter) highly luminescent nanoparticles of silicon that provide varying wavelengths of photoluminescence with high quantum down conversion efficiency of short wavelengths (50% to 60%).
When thin films of silicon nanoparticles are deposited (sprayed) onto silicon substrates, ultraviolet light is absorbed and converted into electrical current. With appropriate connections, the film acts as nanosilicon photovoltaic solar cells that convert solar radiation to electrical energy.
The process of producing silicon nanoparticles is supported by 10 issued US patents, 7 pending US patents, 2 issued foreign counterpart patents and 19 pending foreign counterpart patents.
For additional information regarding Octillion Corp., please visit http://www.octillioncorp.com or call toll free 800-213-0689 to speak to a shareholder representative.
To receive future press releases via email, please visit:
To view the full HTML text of this release, please visit:
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Octillion Corp. (the “Company” or “Octillion”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Octillion will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov . The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For more information, please click here
Mr. Harmel S. Rayat
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Lithium battery catalyst found to harm key soil microorganism February 7th, 2016
Discovery of the specific properties of graphite-based carbon materials February 6th, 2016
Silicon-based metamaterials could bring photonic circuits February 1st, 2016
Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre: FDA Cleared Immuno-Oncology Technology to Resume Clinical Development for Solid Tumor Patients January 27th, 2016
An alternative to platinum: Iron-nitrogen compounds as catalysts in graphene January 28th, 2016
Nanostructural Changes in Solar Cells to Increase Their Efficiency January 28th, 2016